CASI Pharmaceuticals, Inc. (CASI) is still in bottoming mode. The technical indicators are looking better now for the stock. The MACD is starting to rise, confirming a bullish divergence has taken form and the Stochastic also has a bullish crossover. It might attempt to breakout above the $1.25 level on Monday and if it succeeds we should expect a strong move to...
CASI Pharmaceuticals Inc (NASDAQ:CASI) The daily chart is shaping up and I expect the next point of resistance to be at $2.25. At some point CASI will take off and never look back. I think that day will come soon and those buying at these prices will be thanking me down the road. Oppenheimer analyst Leland Gershell recently raised the price target on CASI to $6.00...
Thursday's earnings report news has lit a fire under CASI Pharmaceuticals (NASDAQ: CASI) and I don't think it will be put out anytime soon. This looks like the start of a prolonged rally, one that could see this stock trading +400% higher than current levels according to Oppenheimer analyst Leland Gershell that yesterday raised the price target on CASI to $6.00...
Strong buying from COB/CEO in March at $2.06 and strong buying last year as well from same insider. Break 1.78, Stop signal 1.47. First target 2.33, Second target Momentum.
CASI Pharmaceuticals Inc (NASDAQ:CASI) moved up about 9.22% on strong volume last week and it looks like a lot of traders booked gains from the upwards run, but I did exactly the opposite. With the resistance level already identified on the charts and with the huge insider activity revealed, I used the pullback to take a big long position. Usually when insiders...
CASI saw a nice bump in after-hours trading Friday. Shares hit $1.88. Can the Oppenheimer analyst rating be enough of a catalyst to carry through this momentum into the week ahead is the biggest question. Great volume on Friday but is it all for nothing? "What had sparked some excitement came in light of new analyst activity. Oppenheimer analyst Leland Gershell...
openinsider. com/search?q=CASI insider BUY CASI Zhang Larry Pres P - Purchase $1.90 +20,153 20,153 New +$38,291 CASI He Wei-Wu COB, CEO, 10% P - Purchase $1.90 +4,152,426 12,809,942 +48% +$7,889,609
Yahoo finance “CASI Pharmaceuticals Inc (CASI), a biopharmaceutical company dedicated to developing high-quality products and therapeutics to the global health market, announced earlier this month that it had received National Medical Products Administration approval of Melphalan Hydrochloride For Injection. CASI Pharmaceuticals Executive Chairman Wei-Wu He,...
Market retreats to 20 period EMA after making new highs (for long positions)/lows (for shorts) with ADX (14period) >30. Some people use the 20 period SMA . Projection is a retest of the highs. Trailing stop. ***Failed grails tend to move (painfully) in the opposite direction. Setup invalid below weekly EMA (5.73)
CASI TIME TO SHORT. It is hitting the red resistance line. Once it hits back the green line we can go long.
CASI has broken the last upward move, so it's possible to see more downside, with a potential test on the previous low. Finished this retrace i'm expecting a strong wave up.